Literature DB >> 20457534

The phenylalanine hydroxylase c.30C>G synonymous variation (p.G10G) creates a common exonic splicing silencer.

Steven F Dobrowolski1, Henriette S Andersen, Thomas K Doktor, Brage S Andresen.   

Abstract

PKU is caused by mutations in PAH. A c.30C>G synonymous variation in exon 1, previously reported as neutral, was observed in two patients. The variation creates a GGG triplet, which is part of several exonic splicing silencer (ESS) motifs. Because the 5'-splice site of PAH exon 1 is intrinsically weak and therefore could be responsive to a new flanking ESS, we hypothesized that c.30C>G could cause aberrant mRNA splicing. We demonstrate that c.30C>G causes aberrant mRNA splicing in two different reporter minigenes, and that this is abolished if a preexisting flanking GGG triplet is disrupted. GGG triplets are part of the consensus motif bound by splicing-inhibitory hnRNPH proteins and we observed a dramatic increase in hnRNPH binding to c.30C>G PAH RNA. We conclude that c.30C>G creates a hnRNPH-binding ESS, which can disrupt mRNA splicing. A disease-causing mutation in HEXB, which has previously been associated with exon skipping in patients also creates a GGG triplet. We show that the mutant HEXB motif causes exon skipping of a reporter minigene and that this is also influenced by a flanking GGG triplet. We suggest that aberrant splicing caused by creation/abolishment of GGG triplets located together with a preexisting flanking GGG triplet, may be an underreported cause of human disease. It is important to recognize that exonic sequence changes may disrupt mRNA splicing. This is particularly important in PAH, since PKU patients harboring such mutations are unlikely to respond to therapy with 6R-tetrahydrobiopterin (BH(4)), despite the fact that the genetic code indicates otherwise. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20457534     DOI: 10.1016/j.ymgme.2010.04.002

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  5 in total

1.  Melanoma cases demonstrate increased carrier frequency of phenylketonuria/hyperphenylalanemia mutations.

Authors:  Joshua Arbesman; Sairekha Ravichandran; Pauline Funchain; Cheryl L Thompson
Journal:  Pigment Cell Melanoma Res       Date:  2018-03-12       Impact factor: 4.693

2.  Splice-shifting oligonucleotide (SSO) mediated blocking of an exonic splicing enhancer (ESE) created by the prevalent c.903+469T>C MTRR mutation corrects splicing and restores enzyme activity in patient cells.

Authors:  Bruno Palhais; Veronica S Præstegaard; Rugivan Sabaratnam; Thomas Koed Doktor; Seraina Lutz; Patricie Burda; Terttu Suormala; Matthias Baumgartner; Brian Fowler; Gitte Hoffmann Bruun; Henriette Skovgaard Andersen; Viktor Kožich; Brage Storstein Andresen
Journal:  Nucleic Acids Res       Date:  2015-04-15       Impact factor: 16.971

3.  Intronic PAH gene mutations cause a splicing defect by a novel mechanism involving U1snRNP binding downstream of the 5' splice site.

Authors:  Ainhoa Martínez-Pizarro; Maja Dembic; Belén Pérez; Brage S Andresen; Lourdes R Desviat
Journal:  PLoS Genet       Date:  2018-04-23       Impact factor: 5.917

4.  The Splicing Efficiency of Activating HRAS Mutations Can Determine Costello Syndrome Phenotype and Frequency in Cancer.

Authors:  Anne-Mette Hartung; Jeff Swensen; Inaki E Uriz; Morten Lapin; Karen Kristjansdottir; Ulrika S S Petersen; Jeanne Mari V Bang; Barbara Guerra; Henriette Skovgaard Andersen; Steven F Dobrowolski; John C Carey; Ping Yu; Cecily Vaughn; Amy Calhoun; Martin R Larsen; Lars Dyrskjøt; David A Stevenson; Brage S Andresen
Journal:  PLoS Genet       Date:  2016-05-19       Impact factor: 5.917

5.  Global identification of hnRNP A1 binding sites for SSO-based splicing modulation.

Authors:  Gitte H Bruun; Thomas K Doktor; Jonas Borch-Jensen; Akio Masuda; Adrian R Krainer; Kinji Ohno; Brage S Andresen
Journal:  BMC Biol       Date:  2016-07-05       Impact factor: 7.431

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.